BIOMAT Database Logo BIOMAT Database Logo

Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor. 1978

J Mendlewicz, and M B Youdim

UI MeSH Term Description Entries
D007258 Informed Consent Voluntary authorization, by a patient or research subject, with full comprehension of the risks involved, for diagnostic or investigative procedures, and for medical and surgical treatment. Consent, Informed
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J Mendlewicz, and M B Youdim
Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged rats.
June 1991, Pharmacology, biochemistry, and behavior,
J Mendlewicz, and M B Youdim
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.
January 1975, Journal of neural transmission,
J Mendlewicz, and M B Youdim
Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor, in endogenous and nonendogenous depression.
October 1982, Psychopharmacology bulletin,
J Mendlewicz, and M B Youdim
(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
January 2004, Neurotoxicology,
J Mendlewicz, and M B Youdim
L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
January 1990, Advances in neurology,
J Mendlewicz, and M B Youdim
Responses of forebrain neurons to the MAO-B blocker L-deprenyl.
January 1995, Brain research bulletin,
J Mendlewicz, and M B Youdim
The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine.
July 1994, Brain research,
J Mendlewicz, and M B Youdim
Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal.
October 1994, Synapse (New York, N.Y.),
J Mendlewicz, and M B Youdim
L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression.
March 1980, Life sciences,
J Mendlewicz, and M B Youdim
Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency.
February 1986, Xenobiotica; the fate of foreign compounds in biological systems,
Copied contents to your clipboard!